The metabolic response to human growth hormone (HGH) was studied in five obese subjects in the fed state and during prolonged (5-6 wk) starvation. In the fed state (three subjects), HGH induced an elevation in basal serum insulin concentration, a minimal increase in blood and urine ketone levels, and a marked reduction in urinary nitrogen and potassium excretion resulting in positive nitrogen and potassium balance.
A B S T R A C T The metabolic response to human growth hormone (HGH) was studied in five obese subjects in the fed state and during prolonged (5-6 wk) starvation. In the fed state (three subjects), HGH induced an elevation in basal serum insulin concentration, a minimal increase in blood and urine ketone levels, and a marked reduction in urinary nitrogen and potassium excretion resulting in positive nitrogen and potassium balance.
In prolonged fasting (four subjects), HGH administration resulted in a 2-to 3-fold increase in serum insulin which preceded a 50% elevation in blood glucose.
Persistence of the lipolytic effects of HGH was indicated by a rise in free fatty acids and glycerol. The response differed markedly from the fed state in that blood P-hydroxybutyrate and acetoacetate levels rose by 20-40%, resulting in total blood ketone acid concentrations of 10-12 mmoles/liter, ketonuria of 150-320 mmoles/day, and increased urinary potassium loss. The subjects complained of nausea, vomiting, weakness, and myalgias.
Despite a 50% reduction in urea excretion during HGH administration, total nitrogen loss remained unchanged as urinary ammonia excretion rose by 50% and correlated directly with the degree of ketonuria.
It is concluded that in prolonged starvation (a) HGH may have a direct insulinotropic effect on the beta cell independent of alterations in blood glucose concentration, 
INTRODUCTION
In recent years growth hormone has been implicated in the regulation of body fat mobilization (1) and in blood glucose homeostasis (2) . With regard to protein metabolism, it has been postulated that growth hormone is not only responsible for the anabolism characteristic of young growing individuals, but also plays a role in fully grown subjects in conserving body protein stores during periods of starvation or restricted food intake (3).
Recent studies from our laboratory have demonstrated that obese subjects undergoing prolonged therapeutic starvation do, indeed, conserve body protein as indicated by a reduction in urinary nitrogen excretion from levels of 10-15 g/day in the 1st wk of fasting to levels of 3-5 g/day after 5 wk of starvation (4) . Furthermore, as demonstrated by indirect calorimetry, these subjects utilize no carbohydrate stores but derive almost all their caloric requirements from dissolution of body fat (5) . While this constellation of enhanced fat utilization, diminished carbohydrate consumption, and minimal protein catabolism is consistent with the known effects of exogenous growth hormone in the fed state (6) , no significant elevation in serum growth hormone is demonstrable in the starved obese subjects (4) . Similarly in nonobese individuals, after a transient increase in serum levels, growth hormone concentration returns to base line as fasting is extended beyond 5 days (7). The question thus arises as to whether prolonged fasting influences the tissue sensitivity to the protein-sparing effects of so- (Table I) . Each had volunteered to undergo prolonged fasting after failure of various dietary regimens. They were informed of the nature, purpose, and possible risks involved in starvation and growth hormone administration. The screening tests employed to exclude cardiopulmonary, renal, hepatic, or endocrine abnormalities have been reported previously (4) .
The subjects were studied both in the fed state (three subjects) and during prolonged starvation (four subjects). Two subjects were studied in both the fed and fasted state in the sequence demonstrated in Table I . In the fed state, two of the subjects (J.C. and M.L.) received a 2000 kcal, 450 g carbohydrate, low residue, synthetic liquid diet (Vivonex-100; Vivonex Corp., Mountain View, Calif.) for 10-14 days before, during, and for 5 days after administration of growth hormone. Use of this diet eliminated the need for stool collections and analyses in performing balance studies, since these patients passed no stools (save for small amounts of mucoid material) after the 1st wk on the liquid diet. The third subject (M.S.) received a 1200 kcal conventional diet. During starvation, daily intake was Precontrol values represent the mean of three to six observations on each subject during the week preceding HGH administration.
The methods employed for measurement of blood glucose, serum insulin and growth hormone, plasma free fatty acids, total serum CO2, blood glycerol, blood and urinary acetoacetate and 8-hydroxybutyrate, and total nitrogen, urea nitrogen, ammonia nitrogen, and potassium in urine have been described (4, 10) . The paired t test and calculation of the coefficient of correlation were employed in the statistical analyses (11) .
RESULTS
Fed state. The response to growth hormone in the fed state is shown in Fig. 1 and Table II . In all subjects positive nitrogen balance amounting to 2-5 g/day and positive potassium balance were observed (Fig. 1) . Noteworthy is the fact that the decrease in nitrogen loss was due to a reduction in urea excretion with urine ammonia remaining unchanged.
In agreement with previous studies in nonobese individuals (12), HGH administration resulted in an elevation in postabsorptive serum insulin levels in each of the obese subjects. On the other hand, blood glucose levels failed to show a consistent increment. The small but measurable increases observed in blood and urine ketone acids (Table II) are consistent with previous reports in nonfasted subjects (13) .
Starvation. The mean concentrations of circulating hormones and substrates before, during, and after growth hormone administration in prolonged starvation are shown in Table III . Before HGH treatment each of the subjects demonstrated the characteristic metabolic response to prolonged fasting (4), manifested by low levels of growth hormone and a reduction in serum insulin and blood glucose (Fig. 2) . After initiation of treatment, circulating HGH levels were 5-to 10-fold above base line 12 hr after hormone injection. Presumably much higher levels would have been observed had samples been obtained at shorter intervals after hormone injection (14) . A significant elevation in serum insulin (P <0.025) was observed within 24-48 hr of initiation of HGH injection and persisted for 4 days after cessation of treatment. While blood glucose levels also rose to levels significantly above base line (P < 0.025), this elevation clearly lagged behind the insulin response, becoming apparent only after 72 hr of treatment. Plasma free fatty acids exhibited a progressive rise during growth hormone administration which reached its peak after 72 hr of treatment (day 38, P <0.01). That this increase in fatty acid concentration was due to augmented lipolysis in adipose tissue is supported by the parallel rise in blood glycerol. Coincident with the increase in fat mobilization, growth hormone treatment resulted in a marked augmentation in starvation ketosis.
Blood P-hydroxybutyrate levels, which had stabilized before HGH, rose by 40-50% during hormone treatment (P < 0.02), while in three of four subjects, acetoacetate levels rose by 20-30% (P < 0.05) (Fig. 3) . As expected, this increase in organic acids (ketone acids and free fatty acids) was accompanied by a corresponding decrease in serum [HCO3]-and blood pH (Fig. 4) . Interestingly, after cessation of HGH injection, blood P-hydroxybutyrate fell significantly below base line (precontrol) levels (P < 0.01).
The components measured in urine are shown in Table IV (Fig. 5) . That the heightened ketonemia was responsible for the augmented ketonuria is suggested by the direct linear correlation between urine and serunm P-hydroxybutyrate levels (r = 0.535, P = 0.05). In marked contrast to the reduction in urine potassium noted in the fed state, growth hormone treatment in starvation resulted in a 2-to 4-fold increase in urine potassium excretion (Fig. 5 ).
The contrast with the fed state is also evident from the data on urinary excretion of total nitrogen. Unlike the fed state in which HGH induced a marked diminution in total nitrogen loss in urine (Fig. 1) , no significant decrease in total nitrogen excretion was demonstrable during HGH treatment in starvation (Fig. 6) . The diminution observed in two patients after cessation of HGH injection (day 39) was not statistically significant (P > 0.2). That exogenous growth hormone was nevertheless not devoid of effects on protein metabolism during starvation is apparent from the response of urinary urea and ammonia, the primary nitrogenous components of urine. As shown in Fig. 7 and ammonia excretion had plateaued at 1.3-1.5 and 1.6-2.2 g/day, respectively. Injection of growth hormone resulted in a 50% decrease in urea excretion which was maximal 24-48 hr after cessation of hormone administration. In contrast, urine ammonia excretion rose by 50% to a maximal level of 3 g/day and correlated directly with urine 8-hydroxybutyrate excretion (r = 0.728, P < 0.01, Fig. 8 ).
These simultaneous yet oppositely directed effects on urea and ammonia excretion thus served to obliterate any net effect on total nitrogen loss. Although none of the subjects complained of any untoward symptoms when receiving growth hormone in the fed state, all developed nausea, mild vomiting, weakness, and myalgias after 24-48 hr of HGH administration in starvation. The symptoms cleared without specific therapy within 24 hr of cessation of hormone injection. Growth Hormone in Prolonged Starvation 417 DISCUSSION Although the metabolic response to exogenous growth hormone has been well characterized in fed subjects (8, 15, 16) , the present study provides information on the influence of prolonged fasting on this response. As in the fed state, the effects of growth hormone in starvation may be considered in terms of alterations in carbohydrate and insulin metabolism, fatty acid mobilization, and net protein balance.
Persistence of the insulinotropic effect of growth hormone in prolonged fasted man is evident from the marked increment observed in serum insulin levels. Comparable findings have recently been reported in fasted dogs (17) . Since blood glucose levels did not fall in association with the hyperinsulinemia, a concomitant increase in peripheral insulin resistance may be inferred. With respect to the mechanism whereby somatotropin elevates insulin levels, the clear lag in the increase in blood glucose concentration militates against hyperglycemia acting as the mediator of the hyperinsulinemia. Since neither ketones nor free fatty acids (21) . Furthermore, it is likely that the symptoms reported by the fasted subjects resulted from the severe ketoacidosis and potassium loss induced by somatotropin. growth hormone on fat and protein metabolism are mutually antagonistic (24) rather than synergistic (6) . The notion that somatotropin is of physiologic importance in reducing protein catabolism in situations of caloric deprivation is derived primarily from short-term studies in hypophysectomized rats (3) . The failure to observe a diminuation in urinary nitrogen loss with an excess of HGH in the present study, suggests that growth hormone is not the prime regulatory factor responsible for conservation of body protein stores' in man during prolonged fasting. Supporting this conclusion are the low levels of circulating HGH and the demonstration that dwarfs with an isolated deficiency of growth hormone have no greater nitrogen loss during starvation than normal controls. ' The longstanding interest in growth hormone as a diabetogenic factor (25) raises the question as to whether the observations described in the current study are manifestations of a transient HGH-induced diabetic state (idiohyphophyseal diabetes). The latter, however, has been produced in man only' in the case of hypophysectomized subjects and is characterized by hyperglycemia and a reduction in urine nitrogen excretion (26) , neither of which was observed in the present study. Furthermore, it has long been recognized that fasting reduces rather than enhances the diabetogenic effects of growth hormone (25) .
Finally, the figures and tables show significant differences in insulin and glucose levels persisting 1 or more days after cessation of growth hormone administration. Urea nitrogen depression also continues, and there appears to be a reversal in the severity of the base line 1Merimee, T. J., P. Felig, E. B. Marliss, S. E. Fineberg, and G. F. Cahill, Jr. 1971 . Glucose and lipid homeostasis in the absence of human growth hormone. J. Clin. Invest. In press. ketoacidosis as evidenced by decreased serum and urinary levels of P-hydroxybutyrate and acetoacetate. At present only speculation can be given to the meaning of these observations but a physiological basis may be present in view of the sporadic nature of growth hormone release and its induction of "secondary" factors which in turn exert metabolic effects or its initiation of altered enzyme levels with longtime constants.
